Group 1 - Canada Goose's shares rose nearly 7% in premarket trading following reports of bids to take the company private [1] - Bain Capital, the controlling shareholder, is looking to sell its stake in Canada Goose with Goldman Sachs advising on the transaction [1] - The offers to take the Toronto-listed company private are based on confidential information from unnamed sources [2]

Group 1 - Bain Capital, the controlling shareholder of Canada Goose, is receiving bids to take the company private at a valuation of approximately $1.4 billion, with Goldman Sachs advising on the sale [1] - Private equity firms Boyu Capital and Advent International have made verbal offers valuing Canada Goose at around $1.35 billion, based on eight times its 12-month average EBITDA [2] - Other interested buyers include Bosideng International and a consortium formed by FountainVest Capital and Anta Sports Product, which previously acquired Amer Sports in 2019 [3] Group 2 - Industry watchers suggest that privatizing Canada Goose would provide buyers with greater autonomy to restructure the company without the scrutiny of regular financial disclosures [4] - Bain Capital is delaying a decision until more offers are received, with due diligence expected to take less than two months once a buyer is selected [4] - Canada Goose's shares have increased over 21% this year, raising its market value to $1.18 billion, although this is significantly lower than its 2018 peak of $7.7 billion [5] Group 3 - As of March, Bain Capital owned approximately 60.5% of Canada Goose's multiple voting shares, which provide 10 times the voting power of publicly traded stock, giving Bain 55.5% of the total voting power [6]

Carlyle is close to selling HSO to Bain Capital in a deal valuing the Dutch technology services company at about $1 billion https://t.co/ZQcl0ZqOqr ...

Exclusive: Bain Capital is considering an initial public offering of retailer Bob’s Discount Furniture for as soon as later this year https://t.co/GguXdbYaWg ...

Bain Capital is exploring options for Ahlstrom, a Finnish fiber-based specialty materials company, including a potential initial public offering or a sale valuing it at as much as €8 billion ($9.3 billion), according to people familiar with the matter. https://t.co/glsgVp5BFY ...

UnitedHealth Group named Bain Capital executive Wayne DeVeydt its next chief financial officer, starting Sept. 2 https://t.co/1ktt6uz1h1 ...

Core Insights - Bristol Myers (BMY) has partnered with Bain Capital to establish a new independent biopharmaceutical company focused on developing therapies for autoimmune diseases, addressing significant unmet patient needs [1][9] - Bain Capital will invest $300 million in the new company, while BMY will out-license five immunology candidates and retain a nearly 20% equity stake [1][3][9] Summary by Categories Company Developments - The new company will focus on autoimmune disease therapies, with BMY out-licensing five immunology candidates, including three clinical stage candidates and two phase I-ready candidates [2][3] - The most advanced assets include afimetoran, an oral TLR7/8 inhibitor in phase II for systemic lupus erythematosus (SLE), and BMS-986322, an oral TYK2 inhibitor with positive phase II results for plaque psoriasis [2] Financial Aspects - BMY will earn royalties and milestones based on the success of each asset in the new company [3][9] - BMY's shares have decreased by 17.2% year-to-date, contrasting with the industry growth of 0.6% [7][8] - BMY is trading at a price/earnings ratio of 7.59x forward earnings, lower than its historical mean of 8.51x and the large-cap pharma industry's 15.11x [10] Market Competition - BMY faces competition in the immunology space, particularly with its drug Sotyktu competing against Amgen's Otezla in psoriasis [5] - In oncology, BMY competes with major players like Merck, whose Keytruda dominates the immuno-oncology market [6] Future Estimates - The bottom-line estimate for 2025 has been revised down to $6.33 from $6.76 over the past month, with a slight decline in the 2026 estimate as well [11]

LONDON, July 21, 2025 (GLOBE NEWSWIRE) -- Questex’s Resort & Residential Hospitality Forum (R&R Forum), the only event in EMEA dedicated to investment in the resort, leisure, and residential hospitality sectors, is now open for registration. The forum returns to Athens, Greece, on 11–13 November 2025, marking its 10th anniversary with a special edition that brings together over 500 industry leaders, developers, investors, and hospitality professionals for three days of strategic content, high-value networki ...

Bain Capital is already scouting for its next airline after more than tripling its money on the Virgin Australia IPO. Read today's Australia Briefing by @AngusWhitley1 for your daily dose of the best of Bloomberg from Down Under and around the world. https://t.co/92FfxKghZU ...

Bain Capital is scouting for its next airline deal after already more than tripling its money on Virgin Australia https://t.co/c7bFqt8Sx0 ...